Premier Alternatives

Renasant Bio

Berkeley, CA · Founded 2022 · Privately Held (backing)

Operator of a biopharmaceutical research platform intended to develop oral small-molecule therapies for genetic kidney disorders. Renasant Bio is based in Berkeley, CA and was founded in 2022. It was valued at $78 million at its seed round in Jun 2025, the last priced event on record. It has raised $55.5 million across 2 recorded rounds; the latest was a $30 million early-stage round in Jun 2025.

PMV mark · valuation
$78.0M
Oct 2026
Priced at
its seed round
Jun 2025
Total raised
$55.5M
Last round
Early Stage VC
Jun 2025

Renasant Bio key facts

as of Oct 2026
  • Operator of a biopharmaceutical research platform intended to develop oral small-molecule therapies for genetic kidney disorders.
  • Renasant Bio is valued at approximately $78.0M as of Oct 2026, set at its seed round, Jun 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $55.5M across 2 recorded rounds; the latest was Early Stage VC ($30.0M) in Jun 2025.
  • Notable investors include Qiming Venture Partners USA, OrbiMed, Atlas Venture, 5AM Ventures, Yale School of Medicine.
  • Renasant Bio has filed 2 Form Ds with the SEC, most recently Jul 2025 ($25.5M sold to 3 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$78.0M

Valued at $78.0M at its seed round, Jun 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Renasant Bio with a free account
  • ·Watch Renasant Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Renasant Bio funding rounds

2 rounds
Jun 2025Early Stage VC$30.0MSEC filing▮
Jul 2024Early Stage VC$25.5MSEC filing▮
Full funding history →

Renasant Bio valuation

Renasant Bio was valued at $78 million at its seed round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Renasant Bio raised?

Renasant Bio has raised $55.5 million across 2 recorded rounds since 2024. The largest was a $30 million early-stage round in Jun 2025.

Renasant Bio has filed 2 Form Ds with the SEC, most recently in Jul 2025 ($25.5 million sold to 3 investors).

Renasant Bio investors

5 investors are on record for Renasant Bio, including Qiming Venture Partners USA, OrbiMed, Atlas Venture and 5AM Ventures. The early-stage round in Jun 2025 drew 4 investors.

About Renasant Bio

Operator of a biopharmaceutical research platform intended to develop oral small-molecule therapies for genetic kidney disorders. The company's platform advances corrector and potentiator programs that target the underlying biology of autosomal dominant polycystic kidney disease, enabling nephrologists, healthcare providers, and patients with disease-modifying treatment options.

Sector
Healthcare
HQ
Berkeley, CA, United States
Founded
2022
Employees
27
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.